The antibody mAb806 is used to treat glioblastoma, although its mechanism of action has been unknown until now.
The study, published in the journal PNAS, paves the way to extend treatment with mAb806 to more types of tumours and to the development of more personalised therapies.
The Uruguayan newpaper La Diaria has published an article about recent research done by the Molecular Modelling and Bioinformatics Lab at IRB Barcelona. This team has achieved the first stable simulations of DNA crystals, thus allowing the study of the role of each molecular component in the stability and conformation of said crystals. The article includes quotes by Pablo Dans, a postdoctoral researcher at the centre, about the study: "What we want is to see how 3D DNA folding occurs and understand how it correlates with the activity of a specific gene. This kind of work has a great plus in that you can see the DNA structure inside the nucleus, and you can manipulate it in three...
The breakthrough made by researchers at IRB Barcelona allows the study of the role of each molecular component in the stability and conformation of DNA crystals.
The new molecular simulation techniques are expected to reduce the time and cost of obtaining crystals in the laboratory.
Modesto Orozco’s lab has published a paper in Chemical Communications about a therapeutic tool to prevent treatment resistance in breast cancer.
The tool has been tested in tumour cells in vitro and will now need to be tested in animal models before moving on to the development of a valid treatment for patients.
La Razón newspaper has published an article on the grants given by the European Research Council (ERC) to five researchers in Barcelona. Among these grants is the ERC Proof of Concept that Modesto Orozco, head of the Molecular Modelling and Bioinformatics Lab at IRB Barcelona, has received. This grant will allow him to optimise and validate "2shRNA", a tool that can simultaneously attack two therapeutic targets involved in drug resistance pathways and that can also bind to other molecules to enhance their delivery and efficacy.
IRB Barcelona scientist, Modesto Orozco has been granted 150,000 euros to optimise and validate a promising anti-tumour therapeutic tool over 18 months.
The Community Research and Development Information Service of the European Union (CORDIS) has echoed the SimDNA project conducted by Modesto Orozco and funded through an ERC Advanced Grant. The project has developed multiscale DNA simulation technologies to understand in detail the mechanisms that control gene expression.
Link to CORDIS
The programme “24 Horas”, broadcasted by Radio Nacional de España, has interviewed IRB Barcelona researcher Modesto Orozco, co-organiser of the Barcelona Biomed Conference.
From November 13 to 15, this meeting gathered more than twenty experts in the field, with the aim to share advances made in 3D genomics.
Link to Radio Nacional de España (interview starts at 19:40)
Various media, including El Progreso, the Diario de Pontevedra and Biotech Spain, have echoed the Barcelona Biomed Conference. From November 13 to 15, more than twenty experts shared the advances made in 3D genomics, a field that is expected/has the capacity to unravel the underlying causes of many diseases. Modesto Orozco, leader of the Molecular Modelling and Bioinformatics group at IRB Barcelona, was a co-organiser of the event.
Link to Biotech Spain